Item 1st case pre-treatment 1st case post-treatment 2nd case pre-treatment 2nd case post-treatment 3rd case pre-treatment 3rd case post-treatment 4th case pre-treatment 4th case post-treatment 5th case pre-treatment 5th case post-treatment 6th case pre-treatment 6th case post-treatment Proteinuria(g/24h) 2.36 1.23 3.51 1.5 0.65 0.3 1.9 0.83 2.71 2.14 1.67 0.4 Age(y) 8 8 13 13 10.2 10.2 9.5 9.5 13 13 12.3 12.3 GFR ml/min) 84 84 102 102 93 94 86 83 113 110 87 87 aPTT(s) (20-40S) 12.3 18.6 14.1 20.4 12.5 22.5 10.7 17.1 16.1 27 18.3 30 PT(s) (12-14S) 8.5 12.5 6.3 10.4 6.2 8.6 9.1 14.2 7.3 11.3 8.6 13.1 AtⅢ(%) (80-120%) 60.4 61 56.2 90 63.9 81.3 57.4 87.6 53 71.8 63.8 81 Whole blood viscosity(mPa.S) low shear rate 12.67 9.16 14.52 10.21 12.03 9.54 13.25 10.13 12.52 9.92 11.2 10.12 middle shear rate 6.07 5.12 7.45 6.49 6.71 5.46 6.84 6.01 6.79 5.73 6.58 5.92 high shear rate 5.05 4.38 5.79 4.81 5.28 4.27 5.61 4.79 5.36 4.35 5.29 4.72 Plasma viscosity(mPa·S) 1.78 1.31 1.85 1.35 1.72 1.24 1.73 1.32 1.71 1.29 1.54 1.21 Whole blood reduced viscosity(mPa·S) low shear rate 21.76 19.24 24.13 20.36 21.26 19.83 22.48 20.17 21.57 19.73 20.63 19.14 middle shear rate 13.29 9.16 14.2 10.25 13.43 9.48 14.21 9.62 13.72 9.73 13.38 10.25 high shear rate 9.25 6.46 10.71 7.32 9.46 6.41 10.06 7.18 9.82 6.72 9.28 7.34 RBC aggregation index 2.65 2.43 3.26 2.84 2.78 2.46 3.15 2.79 2.84 2.57 2.73 2.46

Table 1: Changes in the hemorheology before and after treatment with urokinase for patients with intracranial venous sinus thrombosis complicating nephrotic syndrome.